18F-FD4 PET Reveals α-Synuclein Deposition and Clinical Correlations in Parkinson’s Disease
Objective: This study aimed to determine the potential of a novel α-syn tracer, 18F-FD4 PET, to track regional α-synuclein deposition in PD and explore its…The Diagnostic Value of Dopaminergic-Glucose United PET Imaging in Parkinson’s disease
Objective: This study aimed to evaluate the diagnostic efficacy of DAT-FDG united PET imaging in differentiating PD from other parkinsonian disorders in real-world clinical settings…18F-FD4 PET Reveals α-Synuclein Deposition and Clinical Correlations in Multiple System Atrophy
Objective: This study aimed to determine the potential of 18F-FD4 PET to serve as an in vivo pathology mapping tool for MSA, providing initial proof-of-concept for its use in…Effect of Exenatide on disease progression in early Parkinson’s disease–a randomized, placebo controlled, single-center trial in Sweden
Objective: To identify biological mechanisms that mediate Exenatide's effect in the brain of patients with early Parkinson’s disease(PD). Background: Tracking PD progression remains a major challenge due to…The value of PET imaging in Parkinson’s disease with cognition impairment
Objective: The purpose of this study was to explore the diagnostic value of PET imaging, plasma biomarkers in the diagnosis of cognitive dysfunction in Parkinson's…Decreased cholinergic activity in specific brain regions associated with slower lower limb visual choice reaction time in Parkinson’s disease: A [18F]-FEOBV PET study
Objective: To investigate the relationship between cholinergic system changes, as measured by vesicular acetylcholine transporters (VAChT) [18F] fluoroethoxybenzovesamicol ([18F] FEOBV) binding in PET, and cognitive performance, measured as…Brain Energetics: Changes in Healthy Aging and Parkinson’s Disease
Objective: To identify in vivo bioenergetic alterations in healthy aging and Parkinson’s disease (PD). Background: PD-related cerebral metabolic alterations have been robustly characterized [1] and…Striatal Dysfunction in Parkinson’s Disease Progression: A 18F-9-fluoropropyl-(+)-dihydrotetrabenazine(18F-AV133) PET Study
Objective: To investigate the patterns of striatal 18F-AV133 uptake in relation to disease progression across different stages of PD and to examine its relationship with…Comparison of Microglial PET Imaging in Parkinson’s Disease, RBD, and Controls with a CSF1R and TSPO Ligand.
Objective: To compare regional binding patterns of microglial PET radioligands: [11C]DPA-713, a TSPO ligand, and [11C]CPPC1, a CSF1R ligand in people with Parkinson’s disease (PD).…Dopaminergic and Synaptic Alterations in SWEDD: Insights from [¹⁸F] FE-PE2I and [¹¹C] UCB-J PET Imaging
Objective: To investigate dopaminergic and synaptic density in SWEDD patients compared to idiopathic Parkinson’s disease (IPD) and healthy controls (HCs). Background: Scans Without Evidence of…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 40
- Next Page »